Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease


Deligezer U., Yaman F., Darendeliler E., Dizdar Y., Holdenrieder S., Kovancilar M., ...More

CLINICA CHIMICA ACTA, vol.411, pp.1452-1456, 2010 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 411
  • Publication Date: 2010
  • Doi Number: 10.1016/j.cca.2010.05.040
  • Journal Name: CLINICA CHIMICA ACTA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1452-1456
  • Keywords: Prostate cancer, Metastatic disease, Plasma circulating DNA, Circulating BMP6 mRNA, Free nucleosomes, H3K27 methylation, CELL-FREE DNA, BONE MORPHOGENETIC PROTEIN-6, TUMOR-CELLS, MOLECULAR MARKER, EXPRESSION, PROGRESSION, MECHANISMS, SPREAD, SERUM
  • Istanbul University Affiliated: Yes

Abstract

Background: We evaluated the utility of post-treatment plasma levels of the circulating bone-morphogenetic protein-6-specific mRNA (cBMP6 mRNA), cell-free DNA (cf-DNA), apoptotic nucleosomes and Histone H3 lysine 27 trimethylation (H3K27me3), in discriminating metastatic prostate cancer (PCa) from organ confined, locally controlled disease.